Roche's European-based R&D arm pRED has closed a deal to buy Denmark's Santaris Pharma, paying $250 million upfront with another $200 million up for grabs in potential milestones if the research pays off. The deal marks a big increase in Roche's bet on RNA-targeting drugs, a research sector it exited with great fanfare several years ago as experts debated the potential for the field.
Biotech startup Enumeral Biomedical has pulled off a deal that gives it $21.5 million in financing and access to public markets, paving the way for early-stage work on some cancer immunotherapies.
When Genstar Capital acquired orthopedic implant company Tecomet in December, the private equity firm aimed to build up the company's growth both organically and through acquisitions. It's making good on the latter strategy with the newly announced purchase of the equipment business of Symmetry Medical for $450 million.
Venture capital company Boston Millennia helped close out St. Jude Medical's acquisition of CardioMEMS, a major device aquisition move to join several other important deals the VC finalized this year.
Valeant and Bill Ackman's $54 billion bid for Allergan is definitely a bit unconventional. But is it insider trading? Allergan thinks so--and it's suing to prove it, a move that could hurt Valeant's chances to seal the deal.
Smith & Nephew is targeting a serious margin ramp-up and tax rate reductions within the next few years. Maintaining its aggressive acquisition strategy is an obvious means to work toward both those goals.
3D Systems missed Wall Street earnings expectations because of product delays. The newly disclosed acquisition of Simbionix by 3D Systems for $120 million in cash went largely unnoticed as a consequence; the deal is designed to add 3D virtual reality surgical simulation capabilities to the 3D printer.
While medical device venture activity may have picked up this year, the comparison point in 2013 was abysmally low. In addition, Series A device investment was still shrinking. That's according to a new report from Silicon Valley Bank. These trends are pushing the sector to be more reliant on angel investors, which are becoming more accessible with the advent of crowdfunding, and corporate VCs, who are stealthy but increasingly active.
Meda has staunchly refused every takeover bid that's come its way. But that doesn't mean the Swedish drugmaker isn't interested in M&A. It just prefers to be the buyer. Meda says it's agreed to buy the family-owned Italian drugmaker Rottapharm for about 21.2 billion kronor ($3.1 billion), with an eye on its consumer health offerings.
AstraZeneca has agreed to pay $875 million up front--and up to $2.2 billion total, with milestones--for Almirall's respiratory portfolio. The deal brings a couple of marketed drugs, and a list of pipeline meds that includes a combo drug Almirall is developing with U.S.-based Forest Laboratories.